Literature DB >> 1453987

In vitro activity of fosfomycin against 'problem' gram-positive cocci.

J M Hamilton-Miller1.   

Abstract

Fosfomycin was active in vitro against 54 of 60 'problem' Gram-positive cocci (20 methicillin-resistant Staphylococcus aureus, 20 coagulase-negative staphylococci and 20 enterococci). Its activity was significantly greater under anaerobic conditions, especially against coagulase-negative staphylococci. Mutants resistant to fosfomycin were readily demonstrated, but their growth was prevented by rifampicin or ciprofloxacin. The combinations rifampicin+fosfomycin and ciprofloxacin+fosfomycin showed MIC synergy. It is concluded that fosfomycin in an appropriate combination would be a valuable addition to the small and dwindling range of antibiotics active against problem Gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453987

Source DB:  PubMed          Journal:  Microbios        ISSN: 0026-2633


  11 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 5.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

6.  Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.

Authors:  Q Mei; Y Ye; Y-L Zhu; J Cheng; X Chang; Y-Y Liu; H-R Li; J-B Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-26       Impact factor: 3.267

Review 7.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

8.  Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Authors:  Bruce C Trapnell; Susanna A McColley; Dana G Kissner; Mark W Rolfe; Jonathan M Rosen; Matthew McKevitt; Lisa Moorehead; A Bruce Montgomery; David E Geller
Journal:  Am J Respir Crit Care Med       Date:  2011-11-17       Impact factor: 21.405

9.  Structural and functional characterization of fosfomycin resistance conferred by FosB from Enterococcus faecium.

Authors:  Vanessa Wiltsie; Skye Travis; Madeline R Shay; Zachary Simmons; Patrick Frantom; Matthew K Thompson
Journal:  Protein Sci       Date:  2021-12-22       Impact factor: 6.725

Review 10.  Fosfomycin: Uses and potentialities in veterinary medicine.

Authors:  D S Pérez; M O Tapia; A L Soraci
Journal:  Open Vet J       Date:  2014-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.